H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Capricor Therapeutics (CAPR) today and set a price target of $8.60. The company’s shares closed yesterday at $0.88, close to its 52-week low of $0.66.
Pantginis noted:
“Valuation and potential impediments to achieving it. We reiterate our Buy rating and $8.60 price target. Our price target is based on our clinical net present value (NPV) model, which is currently driven by the company’s lead asset, CAP-1002 in DMD patients. We believe this method is appropriate in capturing the value of the clinical stage pipeline by allowing us to flex multiple assumptions, including chance of success, peak sales estimates, and year of commercial launch.”
According to TipRanks.com, Pantginis has currently no stars on a ranking scale of 0-5 stars, with an average return of -16.9% and a 27.1% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Checkpoint Therapeutics Inc, and Strata Skin Sciences Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Capricor Therapeutics with a $6.30 average price target, a 617.5% upside from current levels. In a report issued on November 14, Maxim Group also maintained a Buy rating on the stock with a $4 price target.
.
See today’s analyst top recommended stocks >>
Capricor Therapeutics’ market cap is currently $27M and has a P/E ratio of 179.18. The company has a Price to Book ratio of 3.87.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Capricor Therapeutics, Inc. engages in the discovery, development and commercialization of first-in-class biological therapies for the treatment of cardiac and other serious medical conditions. Its product candidate consists of CAP-1002, Cenderitide, Exosomes, CAP-1001, CU-NP and CSps.
